Abstract
Introduction
The cytotoxics market is mature and characterized by an increasing level of
genericization. Several blockbuster products will undergo patent expiry during
the forecast period, however, by virtue of these drugs' success, generic entry
will ensure continued growth. Coupled with the launch of several new brands,
steady growth of the cytotoxics market will occur to 2018, at a CAGR of 3.1%.
Key reasons to purchase this research
- Quantify the performance of each of the marketed cytotoxic therapy cancer
brands in the seven major markets over the period 2008 to 2018
- Acquire a detailed account of cytotoxic therapy cancer brand dynamics and
the events that drive and limit their market growth
- Benchmark the cytotoxic therapy cancer brands against their generics and
rest of class and align their 7MM performance with a rest of world snapshot
Table of Contents
OVERVIEW
- This product contains forecasts for cytotoxic therapies across the seven
major markets from 2009 to 2018. It has been designed for delivery in an excel
data pack format, but for more detail about this disease area please see the
accompanying Commercial Insight: Cytotoxic Therapies word document and
PowerPoint executive presentation (DMHC2523).
- The associated report and PowerPoint presentation can be found under
Latest research in the Knowledge centre, through the search function or by
contacting your sales representative.
- Please select the data pack option from the download menu at the side of
the page to access the model.
- Introduction
- Scope of this research
- Research and analysis highlights
- Key reasons to read this report
- Forecasting methodology
- The forecasting model
- General event information
- Event selection and quantification
- Event parameters
| 
